Pyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer

Reuters12-18 20:00

<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer

Pyxis Oncology Inc. announced positive preliminary Phase 1 clinical trial data for Micvotabart Pelidotin (MICVO) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed a 46% confirmed objective response rate $(ORR)$ and a 92% disease control rate (DCR) with MICVO as monotherapy in second-line or later (2L+) R/M HNSCC at 5.4 mg/kg. In combination with KEYTRUDA® (pembrolizumab), MICVO demonstrated a 71% confirmed ORR and 100% DCR in first-line and second-line or later (1L/2L+) R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg. These preliminary results were presented during a live conference call and webcast hosted by the company. Updated data from the ongoing Phase 1 monotherapy study are expected in mid-2026, while further updates from the Phase 1/2 combination study are anticipated in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604050-en) on December 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592084369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592084369","market":"nz","top_or_hot":-1,"title":"Pyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pyxis Oncology Inc. announced positive preliminary Phase 1 clinical trial data for Micvotabart Pelidotin (MICVO) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed a 46% confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> and a 92% disease control rate (DCR) with MICVO as monotherapy in second-line or later (2L+) R/M HNSCC at 5.4 mg/kg. In combination with KEYTRUDA® (pembrolizumab), MICVO demonstrated a 71% confirmed ORR and 100% DCR in first-line and second-line or later (1L/2L+) R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg. These preliminary results were presented during a live conference call and webcast hosted by the company. Updated data from the ongoing Phase 1 monotherapy study are expected in mid-2026, while further updates from the Phase 1/2 combination study are anticipated in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604050-en) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pyxis Oncology Inc. announced positive preliminary Phase 1 clinical trial data for Micvotabart Pelidotin (MICVO) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed a 46% confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> and a 92% disease control rate (DCR) with MICVO as monotherapy in second-line or later (2L+) R/M HNSCC at 5.4 mg/kg. In combination with KEYTRUDA® (pembrolizumab), MICVO demonstrated a 71% confirmed ORR and 100% DCR in first-line and second-line or later (1L/2L+) R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg. These preliminary results were presented during a live conference call and webcast hosted by the company. Updated data from the ongoing Phase 1 monotherapy study are expected in mid-2026, while further updates from the Phase 1/2 combination study are anticipated in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604050-en) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLb73dqB:1","article_id":"2592084369","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592084369","pubTimestamp":1766059226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pyxis Oncology Inc. announced positive preliminary Phase 1 clinical trial data for Micvotabart Pelidotin  in patients with recurrent or metastatic head and neck squamous cell carcinoma . The results showed a 46% confirmed objective response rate  and a 92% disease control rate  with MICVO as monotherapy in second-line or later (2L+) R/M HNSCC at 5.4 mg/kg. In combination with KEYTRUDA , MICVO demonstrated a 71% confirmed ORR and 100% DCR in first-line and second-line or later  R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg. These preliminary results were presented during a live conference call and webcast hosted by the company. Updated data from the ongoing Phase 1 monotherapy study are expected in mid-2026, while further updates from the Phase 1/2 combination study are anticipated in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","BK4139":"生物科技","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","PYXS":"Pyxis Oncology, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Pyxis Oncology报告MICVO治疗头颈癌的初步1期结果呈阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":0.9,"NDAQ":0.9},"content_text":"Pyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer\n    \n\n        Pyxis Oncology Inc. announced positive preliminary Phase 1 clinical trial data for Micvotabart Pelidotin (MICVO) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed a 46% confirmed objective response rate $(ORR)$ and a 92% disease control rate (DCR) with MICVO as monotherapy in second-line or later (2L+) R/M HNSCC at 5.4 mg/kg. In combination with KEYTRUDA® (pembrolizumab), MICVO demonstrated a 71% confirmed ORR and 100% DCR in first-line and second-line or later (1L/2L+) R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg. These preliminary results were presented during a live conference call and webcast hosted by the company. Updated data from the ongoing Phase 1 monotherapy study are expected in mid-2026, while further updates from the Phase 1/2 combination study are anticipated in the second half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604050-en) on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592084369","isCrawlerRequest":true}